腎移植治療薬の世界市場 - 市場考察、競合情勢、市場予測（2032年）

世界の腎移植治療薬の市場規模は、2024年に113億5,970万米ドルであり、2032年までに183億9,830万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで6.29%の成長が見込まれます。腎移植治療薬の需要は、複数の要因によって促進されています。その最たるものは、慢性腎臓病（CKD）、腎不全、末期腎不全（ESRD）の有病率が上昇する中、世界中で腎移植の実施件数が増加していることです。これらの疾患はしばしば腎機能の永続的な障害につながるため、移植へのニーズが高まります。また、研究開発活動が活発化や、移植拒絶反応の予防を目的とした新製品の導入も、市場成長に大きく寄与しています。主要製薬企業による治療製品の革新と拡大への取り組みは、腎移植治療薬市場に有利な環境を作り出しています。こうした動向もあり、市場は2025年～2032年に健全かつ着実に拡大するものとみられます。

腎移植治療薬の市場力学

World Health Organization Global Observatory on Donation and Transplantation（2024）のデータによると、2023年に腎臓、肝臓、心臓などの臓器移植が世界で約17万2,409件行われました。腎移植が11万1,135件で大半を占め、2022年に世界で実施された腎移植10万2,090件から9%の顕著な増加となっています。2023年に実施された腎移植のうち、GODTのデータによると、4万3,101件が生体ドナーによるもので、6万8,034件が死亡ドナーによるものでした。このような移植手術の増加傾向は、臓器拒絶反応を防ぎ、移植片の長期生存を確保する上で重要な、効果的な移植後ケアへのニーズが世界的に高まっていることを明示しています。

移植後の管理の要は、一般に抗拒絶反応薬と呼ばれる免疫抑制剤の使用です。これらの治療薬は、移植された腎臓を異物と認識する免疫系の自然な反応を抑制することにより、腎移植の成功に重要な役割を果たしています。免疫抑制剤がなければ、この免疫反応が移植片の損傷や完全な拒絶反応につながる可能性があります。通常、これらの薬剤は急性拒絶反応と慢性拒絶反応の両方のリスクを軽減するために長期にわたって投与されます。

腎移植の件数が増加している国もあります。例えば、Kidney Care UK（2022）のデータによると、英国では年間約3,600件の腎移植が行われている一方、約5,000人が待機リストに残っていると報告されています。同様にオーストラリアでは、Australian Institute of Health and Welfare（2024）が、2022年に938件の腎移植が行われ、その90%が初回移植であったと報告しています。そのうち713件（76%）が死亡ドナーから、225件（24%）が生体ドナーからでした。腎移植手術の世界的な増加により、包括的かつ長期的な腎移植治療に対する需要も並行して増加しています。これには、免疫抑制剤や抗感染剤だけでなく、移植の転帰を向上させることを目的とした技術革新も含まれます。

さらに、製品開発と規制当局の承認が移植治療薬市場の成長を促進しています。例えば2024年3月、腎臓病治療に特化した臨床段階のバイオテクノロジー企業であるUnicycive Therapeutics, Inc.は、米国食品医薬品局（FDA）がUNI-494に希少疾病用医薬品指定（ODD）を付与したと発表しました。この治験薬は、腎移植後の重篤な合併症である移植片機能遅延（DGF）を予防することを目的としています。

しかし、腎移植治療薬に関連する長期的なリスクや潜在的な副作用、医薬品承認に対する厳しい規制要件などが、腎移植治療薬市場の成長を制限する可能性のある重要な抑制要因となっています。

北米が腎移植治療薬市場全体を独占すると予測される

複数の要因により、北米が2024年に腎移植治療薬市場で最大のシェアを占めると予測されます。この地域の優位性の主因は、CKDやESRDなどの腎疾患の有病率の上昇、腎移植件数の増加、確立された医療インフラ、主要企業による継続的な製品開発です。これらの要因により、北米が世界の腎移植治療薬市場において主導的な地位を占めています。

当レポートでは、世界の腎移植治療薬市場について調査分析し、市場規模と予測、過去3年の製品/技術開発、市場の主要企業、利用可能な機会などの情報を提供しています。

目次

第1章 腎移植治療薬市場レポートのイントロダクション

第2章 腎移植治療薬市場のエグゼクティブサマリー

• 市場の概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 腎移植治療薬市場の主な要因の分析

• 腎移植治療薬市場の促進要因
• 腎移植治療薬市場の抑制要因と課題
• 腎移植治療薬市場の機会

第6章 腎移植治療薬市場のポーターのファイブフォース分析

第7章 腎移植治療薬市場の評価

• 薬剤クラス別
  • カルシニューリン阻害薬
  • インターロイキン阻害薬
  • mTOR阻害薬
  • イノシン一リン酸脱水素酵素（IMPDH）阻害薬
  • その他
• 投与経路
  • 経口
  • 非経口
• モダリティ別
  • 小分子
  • 生物学的製剤
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 腎移植治療薬市場の企業と製品のプロファイル

• Novartis AG
• Sanofi
• Astellas Pharma Inc.
• Asahi Kasei Corporation
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• GSK plc
• Biogen
• Zydus Group
• Eledon Pharmaceuticals, Inc.
• AbbVie Inc.
• CSL
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Renal Transplant Therapeutics Market in Global (2022-2032)
• Table 3: Renal Transplant Therapeutics Market in Global by Drug Class (2022-2032)
• Table 4: Renal Transplant Therapeutics Market in Global by Route of Administration (2022-2032)
• Table 5: Renal Transplant Therapeutics Market in Global by Modality (2022-2032)
• Table 6: Renal Transplant Therapeutics Market in Global by Geography (2022-2032)
• Table 7: Renal Transplant Therapeutics Market in North America (2022-2032)
• Table 8: Renal Transplant Therapeutics Market in the United States (2022-2032)
• Table 9: Renal Transplant Therapeutics Market in Canada (2022-2032)
• Table 10: Renal Transplant Therapeutics Market in Mexico (2022-2032)
• Table 11: Renal Transplant Therapeutics Market in Europe (2022-2032)
• Table 12: Renal Transplant Therapeutics Market in France (2022-2032)
• Table 13: Renal Transplant Therapeutics Market in Germany (2022-2032)
• Table 14: Renal Transplant Therapeutics Market in United Kingdom (2022-2032)
• Table 15: Renal Transplant Therapeutics Market in Italy (2022-2032)
• Table 16: Renal Transplant Therapeutics Market in Spain (2022-2032)
• Table 17: Renal Transplant Therapeutics Market in the Rest of Europe (2022-2032)
• Table 18: Renal Transplant Therapeutics Market in Asia-Pacific (2022-2032)
• Table 19: Renal Transplant Therapeutics Market in China (2022-2032)
• Table 20: Renal Transplant Therapeutics Market in Japan (2022-2032)
• Table 21: Renal Transplant Therapeutics Market in India (2022-2032)
• Table 22: Renal Transplant Therapeutics Market in Australia (2022-2032)
• Table 23: Renal Transplant Therapeutics Market in South Korea (2022-2032)
• Table 24: Renal Transplant Therapeutics Market in Rest of Asia-Pacific (2022-2032)
• Table 25: Renal Transplant Therapeutics Market in the Rest of the World (2022-2032)
• Table 26: Renal Transplant Therapeutics Market in the Middle East (2022-2032)
• Table 27: Renal Transplant Therapeutics Market in Africa (2022-2032)
• Table 28: Renal Transplant Therapeutics Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Renal Transplant Therapeutics Market in Global (2022-2032)
• Figure 3: Renal Transplant Therapeutics Market in Global by Drug Class (2022-2032)
• Figure 4: Renal Transplant Therapeutics Market in Global by Route of Administration (2022-2032)
• Figure 5: Renal Transplant Therapeutics Market in Global by Modality (2022-2032)
• Figure 6: Renal Transplant Therapeutics Market in Global by Geography (2022-2032)
• Figure 7: Renal Transplant Therapeutics Market in North America (2022-2032)
• Figure 8: Renal Transplant Therapeutics Market in the United States (2022-2032)
• Figure 9: Renal Transplant Therapeutics Market in Canada (2022-2032)
• Figure 10: Renal Transplant Therapeutics Market in Mexico (2022-2032)
• Figure 11: Renal Transplant Therapeutics Market in Europe (2022-2032)
• Figure 12: Renal Transplant Therapeutics Market in France (2022-2032)
• Figure 13: Renal Transplant Therapeutics Market in Germany (2022-2032)
• Figure 14: Renal Transplant Therapeutics Market in United Kingdom (2022-2032)
• Figure 15: Renal Transplant Therapeutics Market in Italy (2022-2032)
• Figure 16: Renal Transplant Therapeutics Market in Spain (2022-2032)
• Figure 17: Renal Transplant Therapeutics Market in the Rest of Europe (2022-2032)
• Figure 18: Renal Transplant Therapeutics Market in Asia-Pacific (2022-2032)
• Figure 19: Renal Transplant Therapeutics Market in China (2022-2032)
• Figure 20: Renal Transplant Therapeutics Market in Japan (2022-2032)
• Figure 21: Renal Transplant Therapeutics Market in India (2022-2032)
• Figure 22: Renal Transplant Therapeutics Market in Australia (2022-2032)
• Figure 23: Renal Transplant Therapeutics Market in South Korea (2022-2032)
• Figure 24: Renal Transplant Therapeutics Market in Rest of Asia-Pacific (2022-2032)
• Figure 25: Renal Transplant Therapeutics Market in the Rest of the World (2022-2032)
• Figure 26: Renal Transplant Therapeutics Market in the Middle East (2022-2032)
• Figure 27: Renal Transplant Therapeutics Market in Africa (2022-2032)
• Figure 28: Renal Transplant Therapeutics Market in South America (2022-2032)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Marker Opportunities
• Figure 32: PORTER'S Five Force Analysis

Renal Transplant Therapeutics Market by Drug Class (Calcineurin Inhibitors, Interleukin Inhibitors, mTOR Inhibitors, IMPDH Inhibitors, and Others), Route of Administration (Oral and Parenteral), Modality (Small Molecule and Biologics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing number of kidney transplant performed globally and the rising prevalence of chronic kidney disease, renal failure, end-stage renal disease (ESRD) and its associated risk factors.

The renal transplant therapeutics market was valued at USD 11,359.70 million in 2024, growing at a CAGR of 6.29% during the forecast period from 2025 to 2032 to reach USD 18,398.30 million by 2032. The demand for renal transplant therapeutics is being driven by several key factors. Foremost among these is the growing number of kidney transplants performed globally, alongside the rising prevalence of chronic kidney disease (CKD), renal failure, and end-stage renal disease (ESRD). These conditions often lead to permanent damage to kidney function, thereby increasing the need for transplantation. In addition, a surge in research and development activities, along with the introduction of new products aimed at preventing transplant rejection, is contributing significantly to market growth. The efforts by leading pharmaceutical companies to innovate and expand their therapeutic offerings are creating a favorable environment for the renal transplant therapeutics market. Together, these trends are positioning the market for robust and steady expansion from 2025 to 2032.

Renal Transplant Therapeutics Market Dynamics:

According to the data provided by the World Health Organization Global Observatory on Donation and Transplantation (2024), in 2023, approximately 172,409 organ transplants were performed worldwide, including kidney, liver, heart, and other organs. Kidney transplants accounted for the majority, with 111,135 procedures, a notable 9% increase from the 102,090 kidney transplants conducted globally in 2022. Of the kidney transplants performed in 2023, GODT data revealed that 43,101 were from living donors, while 68,034 were from deceased donors. This upward trend in transplant procedures highlights an increasing global need for effective post-transplant care, which is critical in preventing organ rejection and ensuring long-term graft survival.

A cornerstone of post-transplant management is the use of immunosuppressant medications, commonly referred to as anti-rejection drugs. These therapies play a vital role in kidney transplant success by suppressing the immune system's natural response to recognize the transplanted kidney as a foreign object. Without immunosuppressants, this immune reaction can lead to graft damage or complete rejection. Typically, these medications are administered long-term to reduce the risk of both acute and chronic rejection episodes.

The growing number of kidney transplants is also increasing in countries. For example, data from Kidney Care UK (2022) reported that approximately 3,600 kidney transplants were performed annually in the United Kingdom, while nearly 5,000 individuals remained on the waiting list. Similarly, in Australia, the Australian Institute of Health and Welfare (2024) reported 938 kidney transplants in 2022, with 90% being first-time transplants. Of these, 713 were from deceased donors (76%), and 225 from living donors (24%). The global rise in kidney transplant procedures is driving a parallel increase in demand for comprehensive and long-term renal transplant therapies. This includes not only immunosuppressants and anti-infective agents but also innovations aimed at improving transplant outcomes.

Moreover, product development and regulatory approvals are fostering growth in the transplant therapeutics market. For instance, in March 2024, Unicycive Therapeutics, Inc., a clinical-stage biotechnology company focused on kidney disease therapies, announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to UNI-494. This investigational therapy is aimed at preventing Delayed Graft Function (DGF), a serious complication following kidney transplantation.

However, the long-term risk and potential adverse effects associated with kidney transplant drugs and stringent regulatory requirements for drug approval, among others, are some of the key constraints that may limit the growth of the renal transplant therapeutics market.

Renal Transplant Therapeutics Market Segment Analysis:

Renal Transplant Therapeutics Market by Drug Class (Calcineurin Inhibitors, Interleukin Inhibitors, mTOR Inhibitors, IMPDH Inhibitors, and Others), Route of Administration (Oral and Parenteral), Modality (Small Molecule and Biologics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug class segment of the renal transplant therapeutics market, the calcineurin inhibitors category is estimated to account for the largest market share in 2024. The growth of the calcineurin inhibitors category is being significantly driven by the rising global cases of kidney transplants and the critical clinical role of calcineurin inhibitors (CNIs) in preventing organ rejection. These agents are well-established, FDA-approved, and remain the cornerstone of immunosuppressive regimens in renal transplantation.

One of the key strengths of calcineurin inhibitors lies in their high efficacy in preventing acute rejection episodes. By targeting the calcineurin pathway, CNIs inhibit T-cell activation and suppress the production of interleukin-2 (IL-2), a cytokine essential for T-cell proliferation. This mechanism significantly lowers the risk of early acute rejection when compared to older immunosuppressive strategies. Beyond acute rejection prevention, CNIs have played a pivotal role in improving long-term graft survival. Their ability to suppress T-cell-mediated immune responses helps mitigate chronic graft injury, a major contributor to late transplant failure.

In clinical practice, CNIs are typically administered as part of a triple immunosuppressive regimen, often in combination with antimetabolites such as mycophenolate mofetil and corticosteroids. This multimodal approach allows physicians to balance efficacy and safety by using lower doses of each agent, thereby reducing drug-specific toxicities while maintaining robust immune suppression.

Among the most prominent calcineurin inhibitors are:

• PROGRAF(R) (tacrolimus) by Astellas Pharma is indicated for the prevention of organ rejection in kidney transplant recipients. It is widely considered a first-line therapy due to its potent immunosuppressive profile.
• NEORAL(R) (cyclosporine capsules, USP) by Novartis is a widely used calcineurin inhibitor, approved to reduce the risk of graft rejection, particularly in patients who may not tolerate tacrolimus or require tailored immunosuppressive management.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of renal transplant therapeutics across the globe.

North America is expected to dominate the overall renal transplant therapeutics market:

North America is projected to hold the largest share of the renal transplant therapeutics market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of kidney diseases such as CKD and ESRD, a growing number of kidney transplants, a well-established healthcare infrastructure, and ongoing product development by leading companies. Collectively, these factors are positioning North America as the leading market in the global renal transplant therapeutics market.

According to the Centers for Disease Control and Prevention (CDC, 2024), in 2023, approximately 35.5 million U.S. adults, about 14% of the population, were living with CKD. Supporting this, the American Kidney Fund (2024) reported that around 808,000 individuals were living with kidney failure, with 135,000 new cases diagnosed in 2022, underscoring the escalating burden of kidney-related conditions in the country.

As per the data from the Kidney Foundation of Canada (2023, every 1 in 10 people, accounting for approximately 4 million people, were suffering from kidney disease in Canada. This growing burden of kidney disease in the region has led to increased transplant procedures, fueling the need for effective immunosuppressive and anti-infective therapies to support long-term graft survival, thereby driving the market growth.

As per the latest data from the Organ Procurement and Transplantation Network (OPTN, 2025), in 2023, over 27,759 kidney transplants were performed in the United States, while the National Kidney Foundation (2023) noted more than 25,000 kidney transplants in 2022 alone. These high transplant volumes are driving demand for renal transplant therapeutics, particularly immunosuppressants and infection-preventive therapies.

Furthermore, key industry players in the region are actively advancing transplant-related drug development. For example, in October 2024, Biogen announced that felzartamab, an investigational anti-CD38 monoclonal antibody, received Breakthrough Therapy Designation (BTD) from the U.S. FDA for treating late antibody-mediated rejection (AMR) in kidney transplant recipients, without concurrent T-cell-mediated rejection.

Therefore, the combination of a rising number of kidney transplant procedures, a high prevalence of kidney disease, and ongoing innovation in transplant therapeutics is expected to significantly propel the growth of the renal transplant therapeutics market in the North America from 2025 to 2032.

Renal Transplant Therapeutics Market Key Players:

Some of the key market players operating in the renal transplant therapeutics market include Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, GSK plc, Biogen, Zydus Group, Eledon Pharmaceuticals, Inc., AbbVie Inc., CSL, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and others.

Recent Developmental Activities in the Renal Transplant Therapeutics Market:

• In March 2025, Zydus announced the launch of ANVIMO (Letermovir), marking a significant advancement in the prevention of Cytomegalovirus (CMV) infection among kidney transplant recipients. ANVIMO offers a safer, well-tolerated, and effective alternative to existing therapies, with superior safety, fewer side effects, and the potential to enhance post-transplant outcomes, making it a valuable addition to renal transplant care.
• In March 2025, Hansa Biopharma AB announced the completion of enrollment for its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label, Phase 3 confirmatory trial in Europe. The study is evaluating one-year patient and graft survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with imlifidase, aiming to further validate the therapy's clinical effectiveness and safety.
• In February 2025, Eledon Pharmaceuticals, Inc. announced that its investigational anti-CD40L antibody, tegoprubart, was utilized as a key component of the immunosuppressive regimen in a groundbreaking xenotransplantation procedure. On January 25, 2025, a patient received a genetically modified pig kidney at Massachusetts General Hospital (MGH), with the transplant performed in collaboration with eGenesis, marking a significant milestone in the advancement of cross-species organ transplantation.

Key takeaways from the renal transplant therapeutics market report study

• Market size analysis for current renal transplant therapeutics market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the renal transplant therapeutics market.
• Various opportunities available for the other competitors in the renal transplant therapeutics market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current renal transplant therapeutics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for renal transplant therapeutics market growth in the coming future?

Target audience who can benefit from this renal transplant therapeutics market report study

• Renal transplant therapeutics product providers
• Research organizations and consulting companies
• Renal transplant therapeutics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in renal transplant therapeutics
• Various end-users who want to know more about the renal transplant therapeutics market and the latest technological developments in the renal transplant therapeutics market.

Frequently Asked Questions for the Renal Transplant Therapeutics Market:

1. What are renal transplant therapeutics?

• Renal transplant therapeutics are drugs used to support kidney transplant patients by preventing organ rejection and ensuring the long-term function of the transplanted kidney. These therapies primarily include immunosuppressive drugs, anti-infective agents, and supportive medications.

2. What is the market for renal transplant therapeutics?

• The renal transplant therapeutics market was valued at USD 11,359.70 million in 2024, growing at a CAGR of 6.29% during the forecast period from 2025 to 2032 to reach USD 18,398.30 million by 2032.

3. What are the drivers for the renal transplant therapeutics market?

• The demand for renal transplant therapeutics is increasing due to the growing number of kidney transplants worldwide and the rising prevalence of chronic kidney disease, renal failure, and end-stage renal disease (ESRD). These conditions often cause permanent kidney damage, leading to a greater need for transplants. Additionally, ongoing R&D efforts and new product launches by key players in transplant rejection drugs are supporting market growth. Together, these factors are expected to drive steady expansion of the renal transplant therapeutics market from 2025 to 2032.

4. Who are the key players operating in the renal transplant therapeutics market?

• Some of the key market players operating in the renal transplant therapeutics market include Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, GSK plc, Biogen, Zydus Group, Eledon Pharmaceuticals, Inc., AbbVie Inc., CSL, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and others.

5. Which region has the highest share in the renal transplant therapeutics market?

• North America is projected to hold the largest share of the renal transplant therapeutics market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of kidney diseases such as CKD and ESRD, a growing number of kidney transplants, a well-established healthcare infrastructure, and ongoing product development by leading companies. Collectively, these factors are positioning North America as the leading market in the global renal transplant therapeutics market.

Table of Contents

1. Renal Transplant Therapeutics Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Renal Transplant Therapeutics Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Renal Transplant Therapeutics Market Key Factors Analysis

• 5.1. Renal Transplant Therapeutics Market Drivers
  • 5.1.1. The growing number of kidney transplant performed globally
  • 5.1.2. The rising prevalence of chronic kidney disease, renal failure, end-stage renal disease (ESRD) and its associated risk factors
  • 5.1.3. Increasing R&D activities and product launches by key players in domain of transplant rejection drugs
• 5.2. Renal Transplant Therapeutics Market Restraints and Challenges
  • 5.2.1. Long-term risk and potential adverse effects associated with kidney transplant drugs
  • 5.2.2. Stringent regulatory requirements for drug approvals
• 5.3. Renal Transplant Therapeutics Market Opportunity
  • 5.3.1. Advances in Personalized immunosuppression and immunoengineering

6. Renal Transplant Therapeutics Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Renal Transplant Therapeutics Market Assessment

• 7.1. By Drug Class
  • 7.1.1. Calcineurin Inhibitors
  • 7.1.2. Interleukin Inhibitors
  • 7.1.3. mTOR Inhibitors
  • 7.1.4. Inosine Monophosphate Dehydrogenase (IMPDH) Inhibitors
  • 7.1.5. Others
• 7.2. By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. By Modality
  • 7.3.1. Small Molecule
  • 7.3.2. Biologics
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.1.2. Canada Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.1.3. Mexico Renal Transplant Therapeutics Market Size in USD million (2022-2032)
  • 7.4.2. Europe
    • 7.4.2.1. France Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.2.2. Germany Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.2.3. United Kingdom Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.2.4. Italy Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.2.5. Spain Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.2.6. Rest of Europe Renal Transplant Therapeutics Market Size in USD million (2022-2032)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.3.2. Japan Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.3.3. India Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.3.4. Australia Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.3.5. South Korea Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.3.6. Rest of Asia-Pacific Renal Transplant Therapeutics Market Size in USD million (2022-2032)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.4.2. Africa Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.4.3. South America Renal Transplant Therapeutics Market Size In USD Million (2022-2032)

8. Renal Transplant Therapeutics Market Company and Product Profiles

• 8.1. Novartis AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Sanofi
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Astellas Pharma Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Asahi Kasei Corporation
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. F. Hoffmann-La Roche Ltd.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Pfizer Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Bristol-Myers Squibb Company
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. GSK plc
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Biogen
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Zydus Group
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Eledon Pharmaceuticals, Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. AbbVie Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. CSL
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Teva Pharmaceutical Industries Ltd.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Johnson & Johnson Services, Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us